BERKELEY, Calif., Sep 9, 2009 – XOMA Ltd.  and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc.  have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite of integrated information and data management systems. Arana has agreed to pay XOMA a fee of $6 million and XOMA will be entitled to milestone payments and royalties on product sales. Under the terms of the collaboration, XOMA will be fully reimbursed for all services it may provide to Arana under the agreement.

Opinion: XOMA has been trading in a tight consolidation pattern with support in the 75-80c range. Using that support as a stop loss level, we would be dipping our toes in the water, watching for a move over $1. The stock needs a good catalyst to get over that level, volume needs to increase too, so for now, XOMA will continue in this tight range.

RZ – Raser Tech Inc

RZ has been on our watch list, the stock has found support around $1.75, if it can hold this level for the next few trading days, we like this one a lot for a quick move over $2.

Raser (NYSE: RZ) is an environmental energy technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology. Raser’s Transportation and Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.